This Small-Cap Biotech Is Gearing Up For A Make-Or-Break Cancer Drug Data Drop

• The trial is testing Tovecimig in combination with Paclitaxel in patients with a rare disease affecting the bile ducts or gallbladder, often detected at an advanced stage.
• The company expects to report progression-free survival and overall survival results.
• Earlier data showed that the combination delivered an overall response rate of 17.1%, compared with 5.3% for Paclitaxel alone.

Compass Therapeutics (CMPX), a biotech company focused on antibody-driven cancer treatments, drew strong retail interest on Monday as investors looked ahead to the upcoming topline data on secondary endpoints from its Phase 2/3 COMPANION-002 trial for advanced biliary tract cancer

The trial is testing Tovecimig in combination with Paclitaxel in patients with biliary tract cancer, a rare disease that affects the bile ducts or gallbladder, and is often detected at a late stage.

At the time of writing, CMPX shares were down around 11% in pre-market trading. The stock has ended lower in five of the last six sessions.

Compass To Launch Separate Trial For Tovecimig

The company expects to report progression-free survival (PFS) and overall survival (OS) results, marking a key milestone for the program. Tovecimig, a bispecific antibody, is being tested in combination with Paclitaxel in patients with advanced biliary tract cancer who have already received prior chemotherapy.

Earlier data showed that the combination delivered an overall response rate of 17.1%, compared with 5.3% for Paclitaxel alone, a statistically significant improvement. The study also demonstrated lower disease progression rates in the combination arm.

The randomized trial enrolled 168 patients, and safety findings to date are consistent with prior studies. Meanwhile, Compass also plans to launch a separate Phase 2 trial in mid-2026 to evaluate Tovecimig across a broader set of Delta-like ligand 4 (DLL4)-positive tumors. DLL4 is a protein that regulates blood vessel growth.

How Did Retail Traders React?

Despite the pre-market slide, retail sentiment on Stocktwits remained ‘extremely bullish’ over the past 24 hours, amid ‘extremely high’ message volumes.

One user said that if the upcoming results beat existing standards, it could meaningfully improve treatment for advanced patients.

The stock is down more than 1% so far in 2026.

For updates and corrections, email newsroom[at]stocktwits[dot]com.